Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
  • Patent number: 10250704
    Abstract: A downtime registration service is discussed herein that enables client systems that rely on electronic record management systems to continue generating records during a downtime event for the electronic record management system without relying on a workaround that requires temporary identifiers or reentry of data. The downtime registration system improves the efficiency and accuracy of electronic systems because workarounds that involve using temporary identifiers, or reentering data collected during the downtime, increase the amount of work done and the chance for errors to be introduced into the records. The client systems are in communication with an outside facility providing advanced services, which track the records generated during normal operation (i.e., not downtime) so that new records created during downtime properly reuse existing record identifiers or assign new identifiers that correspond to the clients' record keeping policies.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 2, 2019
    Assignee: EXPERIAN HEALTH, INC.
    Inventors: Kassandra Marie Kurth, Edmond Chase Pilkington, Abby Curtis
  • Patent number: 10247722
    Abstract: Today, despite current advances in combinatorial therapies such as surgery, radiotherapy and chemotherapy, aggressive cancers remain fatal. Cancer stem-like cells (CSCs) may account for chemotherapy resistance and thus represent a promising therapeutic target. In this context, the present inventors identified essential intracellular pathways favoring the self-renewal and survival of CSCs. More precisely, the present inventors showed that the cytokine co-receptor GP130 acts as a co-receptor for Apelin/APJ signaling and that the interaction of Apelin with APJ/GP130 activates a dual signaling pathway involving the Akt/mTOR and STAT3 transcription factor, thereby promoting CSCs survival and self-renewal. They therefore propose to block these pathways in order to treat patients suffering from tumors containing CSCs, such as glioblastomas. In another aspect, the invention relates to the use of the Apelin expression level for evaluating the survival probability of a subject suffering from glioblastoma.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: April 2, 2019
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Julie Gavard, Eva-Maria Galan-Moya
  • Patent number: 10246507
    Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 2, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Hyun Lee, Soo Yeon Jung, Bo Gyou Kim, Seung Ja Oh, Ji Min Lee
  • Patent number: 10239952
    Abstract: Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-?) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc*(NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 26, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.
    Inventors: David Scheinberg, Jingyi Xiang, Tao Dao, Su Yan, Cheng Liu
  • Patent number: 10233256
    Abstract: An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to ricin toxin, an expression vector including the isolated nucleic acid molecule and a host cell transfected with said isolated nucleic acid molecule or with the expression vector, a pharmaceutical composition including as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule or the immunoconjugate and a pharmaceutically acceptable carrier, excipient or diluent, and a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule, the immunoconjugate or the pharmaceutical composition.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: March 19, 2019
    Assignee: THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
    Inventors: Ohad Mazor, Ronit Rosenfeld, Arie Ordentlich, Tal Noy-Porat
  • Patent number: 10233243
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 19, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Patent number: 10232039
    Abstract: Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: March 19, 2019
    Assignee: Duke University
    Inventors: Paul W. Noble, Dianhua Jiang
  • Patent number: 10233251
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 19, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Patent number: 10233240
    Abstract: Provided are methods of treating fibrotic conditions in a subject by the identification of specific subsets of fibrogenic myofibroblasts, such as portal fibroblasts expressing mesothelin, and diagnostic methods useful for determining fibrosis, and the prognosis of fibrosis.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: March 19, 2019
    Assignee: The Regents of the University of California
    Inventors: Tatiana Kisseleva, David Brenner
  • Patent number: 10233244
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 19, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • Patent number: 10227413
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 12, 2019
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Nels P. Nielson, Heather Brodkin
  • Patent number: 10227334
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 12, 2019
    Assignee: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • Patent number: 10208122
    Abstract: Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: February 19, 2019
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Patent number: 10208108
    Abstract: The invention provides a pharmaceutical composition comprising as an active ingredient a combination of three isolated monoclonal antibodies or any antigen-binding fragment thereof which bind ricin toxin and neutralize its toxic effects, and a pharmaceutically acceptable carrier, excipient or diluent. The invention also provides a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 19, 2019
    Assignee: THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
    Inventors: Ohad Mazor, Ronit Rosenfeld, Arie Ordentlich, Tal Noy-Porat
  • Patent number: 10208096
    Abstract: According to the present invention, a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, there is provided a method for inhibiting platelet aggregation by a platelet aggregating substance, including administering a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability to a subject in need thereof.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 19, 2019
    Assignee: University of Yamanashi
    Inventors: Tomoyuki Sasaki, Toshiaki Shirai, Katsue Inoue
  • Patent number: 10202452
    Abstract: The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: February 12, 2019
    Assignee: Aptevo Research and Development LLC
    Inventors: Philip H Tan, Sateesh K Natarajan, Catherine J McMahan
  • Patent number: 10202374
    Abstract: The present invention relates to 6-aryl-4-phenylamino quinazolines of formula I wherein, R and R? are as herein described. The present invention particularly relates to synthesis and anticancer and phoshpoinositide-3-kinase-? (PI3K-?) inhibitory activity. In addition, the invention relates to methods of using compounds for treating or preventing various cancers such as pancreatic, prostate, breast and melanoma.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: February 12, 2019
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Ram Asrey Vishwakarma, Sandip Bibishan Bharate, Shashi Bhushan, Rammohan Rao Yadav, Santosh Kumar Guru, Prashant Joshi
  • Patent number: 10196458
    Abstract: The present disclosure provides antibodies that specifically bind to circulating and receptor-bound IgE and inhibit IgE-mediated cell activation. The antibodies find use in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: February 5, 2019
    Assignees: The Regents of the University of California, Sixal, Inc.
    Inventors: Ke Zhang, Andrew Saxon
  • Patent number: 10184000
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Patent number: 10183988
    Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
    Type: Grant
    Filed: June 7, 2014
    Date of Patent: January 22, 2019
    Assignee: Duke University
    Inventors: Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, Anthony M. Moody
  • Patent number: 10183997
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: January 22, 2019
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yun Hee Park, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung, Ji Eun Jung, Hyo Jung Choi
  • Patent number: 10184001
    Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: January 22, 2019
    Assignee: Adventist Health System/Sunbelt Inc.
    Inventors: John Francis, Ali Amirkhosravi, Todd Meyer, Liza Robles-Carrillo
  • Patent number: 10183999
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Patent number: 10179821
    Abstract: The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 15, 2019
    Assignee: GENENTECH, INC.
    Inventors: Robert F Kelley, Menno van Lookeren Campagne, Justin M Scheer, Philip E Hass, Devin Tesar
  • Patent number: 10179817
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 15, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Patent number: 10174067
    Abstract: The present disclosure provides a new cytidine derivative having the general formula (I), and applications thereof: As demonstrated by experiments on the growth inhibition effect of the new cytidine derivative of the present invention on HCT-116 colon cancer xenografts in tumor-bearing nude mice, the compound of the present invention has high anti-tumor activity, data of impacts on weight of nude mice bearing human colon cancer HCT-116 and data of mortality rate showed that the toxicity of the compound is comparatively low.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: January 8, 2019
    Assignees: CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD, INNER MONGOLIA PUYIN PHARMACEUTICAL CO., LTD
    Inventors: Daria Yang, Haidong Wang, Xin Liu, Huijuan Wang
  • Patent number: 10174111
    Abstract: According to the present disclosure there are provided compositions and methods for treating malignant tumors, including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody that comprises the presently disclosed antibody heavy and light chain complementarity determining region (CDR) sequences, or an antigen-binding fragment thereof, or a functional equivalent thereof. Further provided for treating an LSR-positive malignancy is an LSR antagonist or an LSR inhibitor such as a nucleic acid. Therapeutic administration of the anti-LSR antibody to a subject having an LSR-positive malignant tumor is also described.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: January 8, 2019
    Assignee: National University Corporation Kochi University
    Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
  • Patent number: 10174102
    Abstract: The present invention relates to novel antibody frameworks with advantageous properties. For example, this invention relates to novel chimeric human antibody light chain frameworks, comprising framework regions I to III from V? and framework region IV from V?, with advantageous properties, such as high stability and reduced aggregation propensity.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: January 8, 2019
    Assignee: Numab Innovation AG
    Inventors: Sebastian Meyer, David Urech
  • Patent number: 10174115
    Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE MONTPELLIER, CISBIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ PARIS-SUD
    Inventors: Daniel Baty, Jean-Philippe Pin, Patrick Chames, Damien Nevoltris, Philippe Rondard, Pauline Scholler, Gérard Mathis
  • Patent number: 10174110
    Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: January 8, 2019
    Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventors: Harry M. Meade, Li-How Chen
  • Patent number: 10167339
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: January 1, 2019
    Assignee: Baylor Research Institute
    Inventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo
  • Patent number: 10166405
    Abstract: A method of image-guided radiotherapy for treatment of a radio-resistant or radio-sensitive tumor. A three-dimensional visualized tumor image is obtained and the boundary of the tumor is identified. A boosted radiation dose of treatment is designated and applied to a boost region within the tumor boundary. A predetermined prescribed radiation dose is simultaneously applied with the boosted radiation dose within the tumor boundary and in a planning target volume region, which is outside of the tumor boundary. The boosted radiation dose outside of the boost region decreases at a boost dose decreasing rate such that the boosted radiation dose is equal to the predetermined prescribed radiation dose at the tumor boundary.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 1, 2019
    Inventor: Nam Nguyen
  • Patent number: 10168327
    Abstract: The present invention relates to the field of medicine, in particular of research and diagnosis. It relates more particularly to a novel tool for detecting antibodies in a biological sample originating from a mammal. This tool, which is in the form of a protein chip, can be used in screening for new targets of interest involved in the occurrence of an autoimmune disease, in particular of a disease affecting the nervous system of a mammal, and also in the diagnosis or the monitoring of the progression of such an autoimmune disease. The invention also relates to a method for producing such a tool and also to kits comprising it and enabling its use.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: January 1, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE RENE DESCARTES PARIS 5, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Florian Lesage, Franck Chatelain, Michel Mazzuca, Veronique Rogemond, Marie-Madeleine Larroque, Jerome Honnorat
  • Patent number: 10166269
    Abstract: The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a ?-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: January 1, 2019
    Assignee: BIG DNA LTD
    Inventors: John Bernard March, Ewan McIntosh Clark
  • Patent number: 10167335
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: January 1, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
  • Patent number: 10160812
    Abstract: The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: December 25, 2018
    Assignee: MedImmune, LLC
    Inventors: John Li, Nazzareno Dimasi, Steven Coats, Melissa Damschroder, Changshou Gao, Godfrey Rainey, Cuihua Gao, Dorin Toader, Lakshmaiah Gingipalli, Fengjiang Wang, Ryan Fleming, Binyam Bezabeh, Andy Qingan Yuan, Srinath Kasturirangan
  • Patent number: 10159675
    Abstract: Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 25, 2018
    Assignee: Celgene Corporation
    Inventors: Patrick Hagner, Anita Gandhi, Michael Pourdehnad
  • Patent number: 10160798
    Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 25, 2018
    Assignees: President and Fellows of Harvard College, UCB Biopharma SPRL
    Inventors: Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson
  • Patent number: 10159660
    Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: December 25, 2018
    Assignee: Oncternal Therapeutics, Inc.
    Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
  • Patent number: 10150818
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: December 11, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Tsui-Ling Hsu, Yi-Wei Lou, Chih-Wei Lin, Shih-Chi Yeh, Chung-Yi Wu, Han-Chung Wu
  • Patent number: 10137121
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 27, 2018
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Patent number: 10131713
    Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 20, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Nadine Tuaillon, Ezio Bonvini
  • Patent number: 10123982
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: November 13, 2018
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10126306
    Abstract: Methods for quantifying biospecimen sample integrity using markers of oxidation (FIG. 1). Under conditions of incomplete blood plasma/serum (P IS) sample freezing (including storage at ?20 ?C), two different forms of oxidation occur spontaneously at protein sulfur atoms—namely S-cysteinylation of free cysteine residues (in which the oxidative event is disulfide bond formation) and sulfoxidation of methionine. Oxidized forms of albumin and apoA-1, SCA and MOA1 are useful markers of biospecimen integrity. The oxidative chemistries of SCA and MOAI are operational in other proteins and polypeptides. Thus, for rare cases in which the use of SCA or MOA1 may be contraindicated, custom designed surrogate peptide probes based on SCA and MOA1 oxidation chemistry may be fortified into samples at collection to serve as exogenous markers of P/S sample integrity.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: November 13, 2018
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Chad Borges, Matthew Schaab, Douglas Rehder
  • Patent number: 10125185
    Abstract: The invention features thrombospondin-1 (TSP-1) polypeptides (e.g., 3TSR-Fc fusion proteins), nucleic acid molecules encoding the TSP-1 polypeptides, and compositions thereof. The invention also features methods of making and using the TSP-1 polypeptides of the invention (e.g., using 3TSR-Fc fusion proteins to treat a subject having a disorder associated with pathological angiogenesis, e.g., cancer, e.g., epithelial ovarian cancer (EOC)).
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: November 13, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., University of Guelph
    Inventors: John W. Lawler, Mark Duquette, James Petrik
  • Patent number: 10117920
    Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: November 6, 2018
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jochen Probst
  • Patent number: 10118965
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (“EGFR”) antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 6, 2018
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yun Hee Park, Hyo Jung Choi, Ji Eun Jung, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung
  • Patent number: 10118959
    Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 6, 2018
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
  • Patent number: 10118969
    Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
    Type: Grant
    Filed: January 30, 2016
    Date of Patent: November 6, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Che Ma, Han-Chung Wu
  • Patent number: RE47150
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: December 4, 2018
    Assignee: Bayer HealthCare LLC
    Inventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska-Goebel, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brückner, Susanne Steinig, Peter Scholz